H. Feldmann and T. Geisbert, Ebola haemorrhagic fever, The Lancet, vol.377, issue.9768, pp.849-62, 2011.
DOI : 10.1016/S0140-6736(10)60667-8

A. Bukreyev, K. Chandran, O. Dolnik, J. Dye, H. Ebihara et al., Discussions and decisions of the 2012???2014 International Committee on Taxonomy of Viruses (ICTV) Filoviridae Study Group, January 2012???June 2013, Archives of Virology, vol.155, issue.4, pp.821-851, 2012.
DOI : 10.1007/s00705-013-1846-9

J. Kuhn, S. Becker, H. Ebihara, T. Geisbert, K. Johnson et al., Proposal for a revised taxonomy of the family Filoviridae: classification, names of taxa and viruses, and virus abbreviations, Archives of Virology, vol.67, issue.12, pp.2083-103, 2010.
DOI : 10.1007/s00705-010-0814-x

A. Ansari, Clinical features and pathobiology of Ebolavirus infection, Journal of Autoimmunity, vol.55, pp.1-9, 2014.
DOI : 10.1016/j.jaut.2014.09.001

J. Choi and M. Croyle, Emerging Targets and Novel Approaches to Ebola Virus Prophylaxis and Treatment, BioDrugs, vol.76, issue.12, pp.565-83, 2013.
DOI : 10.1007/s40259-013-0046-1

G. Dudas and A. Rambaut, Phylogenetic Analysis of Guinea 2014 EBOV Ebolavirus Outbreak, PLoS Currents, vol.6, 2014.
DOI : 10.1371/currents.outbreaks.84eefe5ce43ec9dc0bf0670f7b8b417d

N. Beeching, M. Fenech, and C. Houlihan, Ebola virus disease, BMJ, vol.349, issue.dec10 28, p.7348, 2014.
DOI : 10.1136/bmj.g7348

N. Moyen, L. Thirion, P. Emmerich, A. Dzia-lepfoundzou, H. Richet et al., Risk Factors Associated with Ebola and Marburg Viruses Seroprevalence in Blood Donors in the Republic of Congo, PLOS Neglected Tropical Diseases, vol.2, issue.Suppl 3, p.3833, 2015.
DOI : 10.1371/journal.pntd.0003833.s002
URL : https://hal.archives-ouvertes.fr/hal-01207635

E. Leroy, S. Baize, V. Volchkov, S. Fisher-hoch, M. Georges-courbot et al., Human asymptomatic Ebola infection and strong inflammatory response, The Lancet, vol.355, issue.9222, pp.2210-2215, 2000.
DOI : 10.1016/S0140-6736(00)02405-3

J. Schieffelin, J. Shaffer, A. Goba, M. Gbakie, S. Gire et al., Clinical Illness and Outcomes in Patients with Ebola in Sierra Leone, New England Journal of Medicine, vol.371, issue.22, pp.2092-100, 2014.
DOI : 10.1056/NEJMoa1411680

Y. Yazdanpanah, J. Arribas, and D. Malvy, Treatment of Ebola virus disease, Intensive Care Medicine, vol.371, issue.12, pp.115-122, 2015.
DOI : 10.1007/s00134-014-3529-8
URL : https://hal.archives-ouvertes.fr/hal-01327168

R. Fowler, T. Fletcher, W. Fischer, F. Lamontagne, S. Jacob et al., Caring for Critically Ill Patients with Ebola Virus Disease. Perspectives from West Africa, American Journal of Respiratory and Critical Care Medicine, vol.190, issue.7, pp.733-740, 2014.
DOI : 10.1164/rccm.201408-1514CP

J. Van-griensven, D. Weiggheleire, A. Delamou, A. Smith, P. Edwards et al., The Use of Ebola Convalescent Plasma to Treat Ebola Virus Disease in Resource-Constrained Settings: A Perspective From the Field, Clinical Infectious Diseases, vol.62, issue.1, 2015.
DOI : 10.1093/cid/civ680
URL : https://hal.archives-ouvertes.fr/hal-01213888

T. Li, M. Chan, and N. Lee, Clinical Implications of Antiviral Resistance in Influenza, Viruses, vol.7, issue.9, pp.4929-4973, 2015.
DOI : 10.3390/v7092850

Y. Furuta, B. Gowen, K. Takahashi, K. Shiraki, D. Smee et al., Favipiravir (T-705), a novel viral RNA polymerase inhibitor, Antiviral Research, vol.100, issue.2, pp.446-54, 2013.
DOI : 10.1016/j.antiviral.2013.09.015

L. Oestereich, A. Lüdtke, S. Wurr, T. Rieger, C. Muñoz-fontela et al., Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model, Antiviral Research, vol.105, pp.17-21, 2014.
DOI : 10.1016/j.antiviral.2014.02.014

S. Smither, L. Eastaugh, J. Steward, M. Nelson, R. Lenk et al., Post-exposure efficacy of Oral T-705 (Favipiravir) against inhalational Ebola virus infection in a mouse model, Antiviral Research, vol.104, pp.153-158, 2014.
DOI : 10.1016/j.antiviral.2014.01.012

V. Madelain, L. Oestereich, F. Graw, T. Nguyen, X. De-lamballerie et al., Ebola virus dynamics in mice treated with favipiravir, Antiviral Research, vol.123, pp.70-77, 2015.
DOI : 10.1016/j.antiviral.2015.08.015
URL : https://hal.archives-ouvertes.fr/inserm-01196078

D. Sissoko, Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea, PLOS Medicine, vol.27, issue.1, 2015.
DOI : 10.1371/journal.pmed.1001967.s011
URL : https://hal.archives-ouvertes.fr/hal-01327168

F. Mentré, A. Taburet, J. Guedj, X. Anglaret, S. Keïta et al., Dose regimen of favipiravir for Ebola virus disease, The Lancet Infectious Diseases, vol.15, issue.2, pp.150-151, 2015.
DOI : 10.1016/S1473-3099(14)71047-3

N. Bouazza, J. Treluyer, F. Foissac, F. Mentré, A. Taburet et al., Favipiravir for children with Ebola, The Lancet, vol.385, issue.9968, pp.603-607, 2015.
DOI : 10.1016/S0140-6736(15)60232-X

T. Warren, J. Wells, R. Panchal, K. Stuthman, N. Garza et al., Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430, Nature, vol.47, issue.7496, pp.402-407, 2014.
DOI : 10.1038/nature13027

X. Qiu, G. Wong, J. Audet, A. Bello, L. Fernando et al., Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp, Nature, vol.27, pp.47-53, 2014.
DOI : 10.1086/514305

C. Murin, M. Fusco, Z. Bornholdt, X. Qiu, G. Olinger et al., Structures of protective antibodies reveal sites of vulnerability on Ebola virus, Proc. Natl. Acad. Sci, pp.17182-17189, 2014.
DOI : 10.1073/pnas.1414164111

L. Zeitlin, J. Pettitt, C. Scully, N. Bohorova, D. Kim et al., Enhanced potency of a fucosefree monoclonal antibody being developed as an Ebola virus immunoprotectant, Proc. Natl. Acad. Sci, pp.20690-20694, 2011.

A. European-medicines, Medicinal products under development for the treatment of Ebola In: Interim assessment report -22 Available from, Report, vol.12, 2014.

J. Pettitt, L. Zeitlin, D. Kim, C. Working, J. Johnson et al., Therapeutic Intervention of Ebola Virus Infection in Rhesus Macaques with the MB-003 Monoclonal Antibody Cocktail, Science Translational Medicine, vol.5, issue.199, 2013.
DOI : 10.1126/scitranslmed.3006608

G. Olinger, J. Pettitt, D. Kim, C. Working, O. Bohorov et al., Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques, Proc. Natl. Acad. Sci, pp.18030-18035, 2012.
DOI : 10.1073/pnas.1213709109

X. Qiu, J. Audet, G. Wong, L. Fernando, A. Bello et al., Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb, Scientific Reports, vol.4, p.3365, 2013.
DOI : 10.1038/srep03365

X. Qiu, G. Wong, L. Fernando, J. Audet, A. Bello et al., mAbs and Ad-Vectored IFN-?? Therapy Rescue Ebola-Infected Nonhuman Primates When Administered After the Detection of Viremia and Symptoms, Science Translational Medicine, vol.5, issue.207, pp.207-143, 2013.
DOI : 10.1126/scitranslmed.3006605

P. George, R. Badiger, W. Alazawi, G. Foster, and J. Mitchell, Pharmacology and therapeutic potential of interferons, Pharmacology & Therapeutics, vol.135, issue.1, pp.44-53, 2012.
DOI : 10.1016/j.pharmthera.2012.03.006

J. Bekisz, H. Schmeisser, J. Hernandez, N. Goldman, and K. Zoon, Mini ReviewHuman Interferons Alpha, Beta and Omega, Growth Factors, vol.22, issue.4, pp.243-51, 2004.
DOI : 10.1080/08977190400000833

F. Lin and H. Young, Interferons: Success in anti-viral immunotherapy, Cytokine & Growth Factor Reviews, vol.25, issue.4, pp.369-76, 2014.
DOI : 10.1016/j.cytogfr.2014.07.015

C. Basler and G. Amarasinghe, Evasion of Interferon Responses by Ebola and Marburg Viruses, Journal of Interferon & Cytokine Research, vol.29, issue.9, pp.511-531, 2009.
DOI : 10.1089/jir.2009.0076

G. Wong, G. Kobinger, and X. Qiu, Characterization of host immune responses in Ebola virus infections, Expert Review of Clinical Immunology, vol.10, issue.6, pp.781-90, 2014.
DOI : 10.1586/1744666X.2014.908705

T. Geisbert, L. Hensley, T. Gibb, K. Steele, N. Jaax et al., Apoptosis Induced In Vitro and In Vivo During Infection by Ebola and Marburg Viruses, Laboratory Investigation, vol.235, issue.2, pp.171-86, 2000.
DOI : 10.1126/science.279.5353.1034

E. Jonasch and F. Haluska, Interferon in Oncological Practice: Review of Interferon Biology, Clinical Applications, and Toxicities, The Oncologist, vol.6, issue.1, pp.34-55, 2001.
DOI : 10.1634/theoncologist.6-1-34

E. Radwanski, G. Perentesis, S. Jacobs, E. Oden, M. Affrime et al., Pharmacokinetics of Interferon ??-2b in Healthy Volunteers, The Journal of Clinical Pharmacology, vol.35, issue.5, pp.432-437, 1987.
DOI : 10.1002/j.1552-4604.1987.tb03044.x

M. Rogge, Y. Liu, and G. Galluppi, Interferon beta assessment in non-Chinese and Chinese subjects: Pharmacokinetics and pharmacodynamic activity of an endogenous cytokine are not race dependent, The Journal of Clinical Pharmacology, vol.34, issue.12, pp.1153-61, 2014.
DOI : 10.1002/jcph.311

G. Subramanian, P. Moore, B. Gowen, A. Olsen, D. Barnard et al., Potent in vitro Activity of the Albumin Fusion Type 1 Interferons (Albumin-Interferon-Alpha and Albumin-Interferon-Beta) against RNA Viral Agents of Bioterrorism and the Severe Acute Respiratory Syndrome (SARS) Virus, Chemotherapy, vol.54, issue.3, pp.176-80, 2008.
DOI : 10.1159/000140361

P. Jahrling, T. Geisbert, J. Geisbert, J. Swearengen, M. Bray et al., Evaluation of Immune Globulin and Recombinant Interferon?????2b for Treatment of Experimental Ebola Virus Infections, The Journal of Infectious Diseases, vol.179, issue.s1, pp.224-258, 1999.
DOI : 10.1086/514310

L. Smith, L. Hensley, T. Geisbert, J. Johnson, A. Stossel et al., Interferon-?? Therapy Prolongs Survival in Rhesus Macaque Models of Ebola and Marburg Hemorrhagic Fever, Journal of Infectious Diseases, vol.208, issue.2, pp.310-318, 2013.
DOI : 10.1093/infdis/jis921

X. Qiu, J. Audet, G. Wong, S. Pillet, A. Bello et al., Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques with Monoclonal Antibodies, Science Translational Medicine, vol.4, issue.138, pp.138-81, 2012.
DOI : 10.1126/scitranslmed.3003876

E. Thi, C. Mire, A. Lee, J. Geisbert, J. Zhou et al., Lipid nanoparticle siRNA treatment of Ebola-virus-Makona-infected nonhuman primates, Nature, vol.146, issue.7552, pp.362-367, 2015.
DOI : 10.1038/nature14442

D. Castanotto and J. Rossi, The promises and pitfalls of RNA-interference-based therapeutics, Nature, vol.13, issue.7228, pp.426-459, 2009.
DOI : 10.1038/nature07758

C. Kraft, A. Hewlett, S. Koepsell, A. Winkler, C. Kratochvil et al., The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States, Clinical Infectious Diseases, vol.61, issue.4, pp.496-502, 2015.
DOI : 10.1093/cid/civ334

T. Geisbert, A. Lee, M. Robbins, J. Geisbert, A. Honko et al., Postexposure protection of non-human primates against a lethal Ebola virus challenge with RNA interference: a proof-of-concept study, The Lancet, vol.375, issue.9729, pp.1896-905, 2010.
DOI : 10.1016/S0140-6736(10)60357-1

U. Securities and E. Commission, Tekmira Provides Update on TKM-Ebola-Guinea [Internet] Available from: http://www.sec.gov/Archives, 2015.

A. Heald, P. Iversen, J. Saoud, P. Sazani, J. Charleston et al., Safety and Pharmacokinetic Profiles of Phosphorodiamidate Morpholino Oligomers with Activity against Ebola Virus and Marburg Virus: Results of Two Single-Ascending-Dose Studies, Antimicrobial Agents and Chemotherapy, vol.58, issue.11, pp.6639-6686, 2014.
DOI : 10.1128/AAC.03442-14

P. Iversen, T. Warren, J. Wells, N. Garza, D. Mourich et al., Discovery and Early Development of AVI-7537 and AVI-7288 for the Treatment of Ebola Virus and Marburg Virus Infections, Viruses, vol.4, issue.12, pp.2806-2836, 2012.
DOI : 10.3390/v4112806

T. Warren, K. Warfield, J. Wells, D. Swenson, K. Donner et al., Advanced antisense therapies for postexposure protection against lethal filovirus infections, Nature Medicine, vol.251, issue.9, pp.991-995, 2010.
DOI : 10.1038/nm.2202

T. Warren, C. Whitehouse, J. Wells, L. Welch, A. Heald et al., A Single Phosphorodiamidate Morpholino Oligomer Targeting VP24 Protects Rhesus Monkeys against Lethal Ebola Virus Infection, mBio, vol.6, issue.1, pp.2344-2358, 2015.
DOI : 10.1128/mBio.02344-14

P. Stassens, P. Bergum, Y. Gansemans, L. Jespers, Y. Laroche et al., Anticoagulant repertoire of the hookworm Ancylostoma caninum., Proc. Natl. Acad. Sci, pp.2149-54, 1996.
DOI : 10.1073/pnas.93.5.2149

T. Geisbert, H. Young, P. Jahrling, K. Davis, E. Kagan et al., Mechanisms Underlying Coagulation Abnormalities in Ebola Hemorrhagic Fever: Overexpression of Tissue Factor in Primate Monocytes/Macrophages Is a Key Event, The Journal of Infectious Diseases, vol.188, issue.11, pp.1618-1647, 2003.
DOI : 10.1086/379724

A. De-pont, A. Moons, E. De-jonge, J. Meijers, G. Vlasuk et al., Recombinant nematode anticoagulant protein c2, an inhibitor of tissue factor/factor VIIa, attenuates coagulation and the interleukin-10 response in human endotoxemia, Journal of Thrombosis and Haemostasis, vol.169, issue.1, pp.65-70, 2004.
DOI : 10.1042/CS20010260

G. Vlasuk, A. Bradbury, L. Lopez-kinninger, S. Colón, P. Bergum et al., Pharmacokinetics and anticoagulant properties of the factor VIIa-tissue factor inhibitor recombinant Nematode Anticoagulant Protein c2 following subcutaneous administration in man. Dependence on the stoichiometric binding to circulating factor X, Thromb. Haemost, vol.90, pp.803-815, 2003.

R. Giugliano, S. Wiviott, P. Stone, D. Simon, M. Schweiger et al., Recombinant Nematode Anticoagulant Protein c2 in Patients With Non???ST-Segment Elevation Acute Coronary Syndrome, Journal of the American College of Cardiology, vol.49, issue.25, pp.2398-407, 2007.
DOI : 10.1016/j.jacc.2007.02.065

A. Lee, G. Agnelli, H. Büller, J. Ginsberg, J. Heit et al., Dose-Response Study of Recombinant Factor VIIa/Tissue Factor Inhibitor Recombinant Nematode Anticoagulant Protein c2 in Prevention of Postoperative Venous Thromboembolism in Patients Undergoing Total Knee Replacement, Circulation, vol.104, issue.1, pp.74-82, 2001.
DOI : 10.1161/hc2601.091386

A. Moons, N. Bijsterveld, K. Koch, J. Meijers, J. Tijssen et al., Inhibition of the tissue factor pathway of coagulation by recombinant nematode anticoagulant protein c2 during elective coronary stent implantation, Neth. Heart J, vol.12, pp.48-54, 2004.

T. Geisbert, L. Hensley, P. Jahrling, T. Larsen, J. Geisbert et al., Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys, The Lancet, vol.362, issue.9400, pp.1953-1961, 2003.
DOI : 10.1016/S0140-6736(03)15012-X

M. Hites, A. Dell-'anna, S. Scolletta, and F. Taccone, The challenges of multiple organ dysfunction syndrome and extra-corporeal circuits for drug delivery in critically ill patients, Advanced Drug Delivery Reviews, vol.77, pp.12-21, 2014.
DOI : 10.1016/j.addr.2014.05.007

D. Roberts and R. Hall, Drug absorption, distribution, metabolism and excretion considerations in critically ill adults, Expert Opinion on Drug Metabolism & Toxicology, vol.47, issue.3, pp.1067-84, 2013.
DOI : 10.2165/11636220-000000000-00000

A. Shurtleff, T. Warren, and S. Bavari, Nonhuman primates as models for the discovery and development of ebolavirus therapeutics, Expert Opinion on Drug Discovery, vol.11, issue.3, pp.233-50, 2011.
DOI : 10.1086/514321

. Chimerix, An Open-Label, Multicenter Study of the Safety and Anti Viral Activity of Brincidofovir (BCV, CMX001) for Ebola Virus Disease -Full Text View -ClinicalTrials.gov [Internet] Available from: https://clinicaltrials, p.1, 2015.

T. Warren, R. Jordan, M. Lo, V. Soloveva, A. Ray et al., Nucleotide Prodrug GS-5734 Is a Broad-Spectrum Filovirus Inhibitor That Provides Complete Therapeutic Protection Against the Development of Ebola Virus Disease (EVD) in Infected Non-human Primates, Open Forum Infectious Diseases, vol.2, issue.suppl_1, 2015.
DOI : 10.1093/ofid/ofv130.02

C. Shoemaker, K. Schornberg, S. Delos, C. Scully, H. Pajouhesh et al., Multiple Cationic Amphiphiles Induce a Niemann-Pick C Phenotype and Inhibit Ebola Virus Entry and Infection, PLoS ONE, vol.11, issue.2, p.56265, 2013.
DOI : 10.1371/journal.pone.0056265.s002

G. Gehring, K. Rohrmann, N. Atenchong, E. Mittler, S. Becker et al., The clinically approved drugs amiodarone, dronedarone and verapamil inhibit filovirus cell entry, Journal of Antimicrobial Chemotherapy, vol.69, issue.8, pp.2123-2154, 2014.
DOI : 10.1093/jac/dku091

G. Neveu, R. Barouch-bentov, A. Ziv-av, D. Gerber, Y. Jacob et al., Identification and Targeting of an Interaction between a Tyrosine Motif within Hepatitis C Virus Core Protein and AP2M1 Essential for Viral Assembly, PLoS Pathogens, vol.8, issue.8, p.1002845, 2012.
DOI : 10.1371/journal.ppat.1002845.s001

A. Basu, B. Li, D. Mills, R. Panchal, S. Cardinale et al., Identification of a Small-Molecule Entry Inhibitor for Filoviruses, Journal of Virology, vol.85, issue.7, pp.3106-3125, 2011.
DOI : 10.1128/JVI.01456-10

M. Wolf, A. Freiberg, T. Zhang, Z. Akyol-ataman, A. Grock et al., A broad-spectrum antiviral targeting entry of enveloped viruses, Proc. Natl. Acad. Sci, pp.3157-62, 2010.
DOI : 10.1073/pnas.0909587107

M. Côté, J. Misasi, T. Ren, A. Bruchez, K. Lee et al., Small molecule inhibitors reveal Niemann???Pick C1 is essential for Ebola virus infection, Nature, vol.30, issue.7364, pp.344-352, 2011.
DOI : 10.1038/nature10380

T. Warren, K. Warfield, J. Wells, S. Enterlein, M. Smith et al., Antiviral Activity of a Small-Molecule Inhibitor of Filovirus Infection, Antimicrobial Agents and Chemotherapy, vol.54, issue.5, pp.2152-2161, 2010.
DOI : 10.1128/AAC.01315-09

M. Kinch, A. Yunus, C. Lear, H. Mao, H. Chen et al., FGI-104: A Broad-Spectrum Small Molecule Inhibitor of Viral Infection, Antiviral Research, vol.82, issue.2, pp.87-98, 2009.
DOI : 10.1016/j.antiviral.2009.02.082

M. Aman, M. Kinch, K. Warfield, T. Warren, A. Yunus et al., Development of a broad-spectrum antiviral with activity against Ebola virus, Antiviral Research, vol.83, issue.3, pp.245-51, 2009.
DOI : 10.1016/j.antiviral.2009.06.001

T. Nguyen and J. Guedj, HCV Kinetic Models and Their Implications in Drug Development, CPT: Pharmacometrics & Systems Pharmacology, vol.50, issue.4, pp.231-273, 2015.
DOI : 10.1002/psp4.28

L. Canini and A. Perelson, Viral kinetic modeling: state of the art, Journal of Pharmacokinetics and Pharmacodynamics, vol.5, issue.11, pp.431-474, 2014.
DOI : 10.1007/s10928-014-9363-3

D. Bausch, J. Towner, S. Dowell, F. Kaducu, M. Lukwiya et al., Assessment of the Risk of Ebola Virus Transmission from Bodily Fluids and Fomites, The Journal of Infectious Diseases, vol.196, issue.s2, pp.142-149, 2007.
DOI : 10.1086/520545

J. Varkey, J. Shantha, I. Crozier, C. Kraft, G. Lyon et al., Persistence of Ebola Virus in Ocular Fluid during Convalescence, New England Journal of Medicine, vol.372, issue.25, pp.2423-2430, 2015.
DOI : 10.1056/NEJMoa1500306

C. Tully, T. Lambe, S. Gilbert, and A. Hill, Emergency Ebola response: a new approach to the rapid design and development of vaccines against emerging diseases, The Lancet Infectious Diseases, vol.15, issue.3, pp.356-365, 2015.
DOI : 10.1016/S1473-3099(14)71071-0

M. Martínez, A. Salim, J. Hurtado, and P. Kilgore, Ebola Virus Infection: Overview and Update on Prevention and Treatment, Infectious Diseases and Therapy, vol.211, issue.4, 2015.
DOI : 10.1007/s40121-015-0079-5

A. Henao-restrepo, I. Longini, M. Egger, N. Dean, W. Edmunds et al., Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial, The Lancet, vol.386, issue.9996, pp.857-66, 2015.
DOI : 10.1016/S0140-6736(15)61117-5